Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Research & Development (2016 - 2025)

Spyre Therapeutics' Research & Development history spans 11 years, with the latest figure at $44.6 million for Q4 2025.

  • For Q4 2025, Research & Development fell 11.58% year-over-year to $44.6 million; the TTM value through Dec 2025 reached $171.7 million, up 5.44%, while the annual FY2025 figure was $171.7 million, 5.44% up from the prior year.
  • Research & Development reached $44.6 million in Q4 2025 per SYRE's latest filing, down from $45.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $50.5 million in Q4 2024 to a low of $11.9 million in Q1 2021.
  • Average Research & Development over 5 years is $27.0 million, with a median of $21.0 million recorded in 2023.
  • Peak YoY movement for Research & Development: decreased 19.5% in 2021, then soared 153.54% in 2024.
  • A 5-year view of Research & Development shows it stood at $16.8 million in 2021, then decreased by 15.08% to $14.3 million in 2022, then surged by 136.35% to $33.7 million in 2023, then surged by 49.88% to $50.5 million in 2024, then dropped by 11.58% to $44.6 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Research & Development are $44.6 million (Q4 2025), $45.2 million (Q3 2025), and $40.1 million (Q2 2025).